Radiation plus chemo for pancreatic cancer pain: trial ends early
NCT ID NCT05114213
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding MR-guided radiation to standard chemotherapy could reduce pain in people with metastatic pancreatic cancer. Only 9 participants were enrolled before the study was terminated early. The main goal was to track pain scores over time, but the small size and early stop mean no firm conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MR-guided adaptive stereotactic body radiotherapy (SBRT)
What this could lead to
If it worked, this approach could offer better pain control for people with metastatic pancreatic cancer who are already on chemotherapy.
What could go wrong
The trial was terminated early with only 9 participants, so results are very limited. It is unclear if the radiation adds benefit or causes extra side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Heidelberg, Dep. of Radiation Oncology
Heidelberg, Germany
-
University Hospital of Zurich
Zurich, Switzerland
-
University of Munich, Dep. of Radiation Oncology
Munich, Bavaria, 81377, Germany